Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients (Ethanol)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00563342|
Recruitment Status : Terminated
First Posted : November 26, 2007
Last Update Posted : October 8, 2008
The primary objective of the study is to examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis.
The catheters dysfunction rate is the primary outcome. The dysfunction is defined as partial or complete occlusion or infection associated with dialysis catheter.
As a secondary outcome, the dialysis quality is also examined (urea reduction rate, total ultrafiltration)
|Condition or disease||Intervention/treatment||Phase|
|End Stage Renal Failure, Hemodialysis||Drug: Ethanol||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients|
|Study Start Date :||June 2007|
|Primary Completion Date :||March 2008|
|Study Completion Date :||March 2008|
- The catheters dysfunction rate [ Time Frame: as partial or complete occlusion or infection associated with dialysis catheter ]
- The dialysis quality is also examined (urea reduction rate, total ultrafiltration) [ Time Frame: as partial or complete occlusion or infection associated with dialysis catheter ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00563342
|Clermont-Ferrand, France, 63000|
|Principal Investigator:||Bertrand Souweine, Pr|